Pfizer seeks $1.5B adult market for Prevnar 13

Pfizer has high hopes for Prevnar-13, the vaccine it acquired in its buyout of Wyeth. An FDA panel has already voted in favor of the updated vaccine, and the company is awaiting final approval of the shot for infants and children.

But Martin Mackay, president of of PharmaTherapeutics at Pfizer, predicts that the company's plans for Prevnar-13 won't end there. The pharma giant plans to ask the FDA this year to approve the vaccine for adults older than 50. Approval for that population alone could account for $1.5 billion in sales, and Prevnar-13's annual sales could peak at a whopping $4.5 billion.

- check out the Reuters article

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.